2025年6月13日
Among the numerous diagnostic methods for Helicobacter pylori, quantum dot immunofluorescence can rapidly type and detect Helicobacter pylori, providing a basis for clinical treatment decisions. This article provides a detailed introduction to the application value of quantum dot technology in the typing and detection of Helicobacter pylori.
Our research focuses on developing diagnostic reagents for in vitro immunochromatography. We aim to use quantum dot labeling to enable specific antigen antibody binding for precise HP detection. We have discovered that using quantum dot technology for HP typing detection can really help with the precise treatment of this bacteria.
We will solve the problems of traditional technology being unable to distinguish the virulence of Helicobacter pylori and having complicated operations through quantum dot technology. While judging whether Helicobacter pylori is infected, we can distinguish the strength of virulence and provide individualized treatment plans.
[Instructor] To begin, collect blood in a separation gel tube while taking care to avoid hemolysis. If testing the serum within four hours is not possible, store the sample at a temperature between two and eight degrees Celsius for up to three days. For long-term storage, seal and store the sample below minus 20 degrees Celsius for up to one year. Restore the samples to room temperature and thoroughly mix them before use. Take out the reagent kit and quality control materials and allow them to equilibrate to room temperature. Now, centrifuge the whole blood samples at 1,467 G for 10 minutes. Now, power on the instrument and the operating computer. Launch the corresponding software and log into the software. Verify that the secure digital or SD card lot number matches that of the reagent kit. Insert the SD card into the instrument and select read ID chip in the application for automatic matching. In the application, select the test module. Choose initialization settings to initialize the instrument and wait for the process to complete. Access the instrument's reagent area and remove the test card slot. Now, open the reagent kit and select the required number of test cards. Then, open the foil patches of the test cards and place them in the slot according to the indicated orientation. Reinsert the card slot into the instrument's reagent area. Within the test module, select bidirectional LIS. Enter the manual entry module, click information entry, and input the specific quality control material information. Click generate and place the quality control materials in the designated sample rack, ensuring correct order and orientation. Click start test to initiate QC testing. Now, in the test module, select manual entry to display bidirectional LIS. Place the test samples in the designated sample rack, ensuring proper order and orientation. Click start test. Once testing is completed, the instrument automatically ejects the used test cards, and the operator disposes of them as medical waste. The peak diagrams of two negative samples showed no significant signals at X1-Urease, X2-CagA, or X3-VacA, confirming Helicobacter pylori negative results, while the strong peak at X4-C line indicated valid test results. Two samples positive for urease showed strong signal peaks at X1, confirming Helicobacter pylori type two infection, while X2 and X3 remained at baseline or low signal, indicating negative CagA and VacA antibodies. Three samples positive for urease and also positive for CagA and/or VacA showed high peaks at X1, X2, and X3, indicating helicobacter pylori type one infection. Receiver operating characteristic, or ROC curves, for individual biomarkers and combined indicators showed that combining five indicators with G17, PGI, PCI, PGR, and Helicobacter pylori antibody typing enhanced diagnostic performance with the highest sensitivity and specificity.
查看完整文字稿并访问数千部科学视频
本文讨论了量子点技术在幽门螺杆菌快速分型与检测中的应用,该技术有助于临床治疗决策。文章强调了在幽门螺杆菌检测中使用量子点标记进行精确抗原-抗体结合的优势。
量子点标记技术可实现对幽门螺杆菌(Helicobacter pylori)的快速、多重检测及毒力分型,填补了区分感染状态与致病潜力的关键空白。该技术在诊断转折点处提高了预测的可信度,有助于基于风险的患者分层以及后续的转化医学研究。该技术整合到发现研究和生物标志物工作流程中,使其成为传染病研发项目中可重复使用的平台。
这种基于量子点的免疫层析方法将传染病研究中的早期发现、检测方法开发和转化生物标志物工作流程连接起来。